Torrent Pharmaceuticals FY26 results confirm revenue growth of 21%
The company formally posted audited annual figures and a ₹5,000 cr QIP resolution, both of which were flagged in mid-May.
— 2 earlier stories on Torrent Pharmaceuticals Ltd. →What's new with Torrent Pharmaceuticals Ltd.
- Audited annual results confirm FY26 revenue at ₹13,980 cr and net profit at ₹2,138 cr.
- The board proposed a final dividend of ₹9 per share.
- An enabling resolution for a QIP of up to ₹5,000 cr is set for shareholder approval.
Why this matters for Torrent Pharmaceuticals Ltd.
This filing is a procedural formality. The market had already priced in these figures following Torrent's May 12th earnings announcement.
What we're watching
- Timelines for the QIP launch.
- Shareholder sentiment regarding the ₹5,000 cr equity dilution.
- Management commentary on sustaining 20%+ growth in FY27.
The full read
Torrent Pharmaceuticals closed its FY26 books with a revenue of ₹13,980 crore and a net profit of ₹2,138 crore. Both figures reflect a 21% jump over the previous year. Alongside these audited results, the board recommended a final dividend of ₹9 per share and pushed forward an enabling resolution to raise ₹5,000 crore via a QIP. The numbers contain no surprises. Torrent disclosed the substance of these financials in its earnings release and board intimation back on May 12th. As a result, this filing serves only to formalize previously disseminated data for the record. Investors should treat the document as a procedural close to the fiscal year rather than a source of fresh market intelligence.